NCT06567080

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases

An Open Label, Single Arm Study to Evaluate JWCAR201 Treating B Cell Driven Hematology Malignancy and Autoimmune Diseases

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: RenJi Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

JWCAR201 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR201 in patients with B cell driven hematology malignancy and autoimmune diseases

Detailed description

JWCAR201 is a CD19/CD20 CAR-T product. By targeting both CD19 and CD20, it is expected to overcome some limitations with CD19 or CD20 single target products. In this study, patients with B cell driven hematology malignancy and autoimmune diseases will be enrolled to receive JWCAR201. PK/PD properties and preliminary efficacy and safety will be evaluated. Each subject will receive JWCAR201 once and is followed up for up to 2 years.

Conditions

• B-cell Tumors
• Autoimmune Diseases
• Lupus Erythematosus, Systemic
• Large B-cell Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	JWCAR201	JWCAR201 is a autologous CAR-T targeting CD19/CD20

Timeline

• Start date: 2024-09-01
• Primary completion: 2025-09-01
• Completion: 2027-03-01
• First posted: 2024-08-22
• Last updated: 2024-08-22

Locations

1 site across 1 country: China